Non-hodgkin lymphoma
KR Shankland, JO Armitage, BW Hancock - The Lancet, 2012 - thelancet.com
Lymphomas are solid tumours of the immune system. Hodgkin's lymphoma accounts for
about 10% of all lymphomas, and the remaining 90% are referred to as non-Hodgkin …
about 10% of all lymphomas, and the remaining 90% are referred to as non-Hodgkin …
Molecular pathogenesis of chronic lymphocytic leukemia
G Gaidano, R Foà… - The Journal of clinical …, 2012 - Am Soc Clin Investig
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Here, we
highlight important genetic alterations that contribute to tumorigenesis, clinical progression …
highlight important genetic alterations that contribute to tumorigenesis, clinical progression …
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic …
K Fischer, P Cramer, R Busch, S Böttcher… - Journal of Clinical …, 2012 - ascopubs.org
Purpose We investigated the safety and efficacy of bendamustine and rituximab (BR) in
previously untreated patients with chronic lymphocytic leukemia (CLL). Patients and …
previously untreated patients with chronic lymphocytic leukemia (CLL). Patients and …
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis …
S Böttcher, M Ritgen, K Fischer… - Journal of clinical …, 2012 - ascopubs.org
Purpose To determine the clinical significance of flow cytometric minimal residual disease
(MRD) quantification in chronic lymphocytic leukemia (CLL) in addition to pretherapeutic risk …
(MRD) quantification in chronic lymphocytic leukemia (CLL) in addition to pretherapeutic risk …
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns
Chronic lymphocytic leukemia is characterized by relapse after treatment and chemotherapy
resistance. Similarly, in other malignancies leukemia cells accumulate mutations during …
resistance. Similarly, in other malignancies leukemia cells accumulate mutations during …
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations
J Edelmann, K Holzmann, F Miller… - Blood, The Journal …, 2012 - ashpublications.org
To identify genomic alterations in chronic lymphocytic leukemia (CLL), we performed single-
nucleotide polymorphism–array analysis using Affymetrix Version 6.0 on 353 samples from …
nucleotide polymorphism–array analysis using Affymetrix Version 6.0 on 353 samples from …
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final …
AR Pettitt, R Jackson, S Carruthers, J Dodd… - Journal of Clinical …, 2012 - ascopubs.org
Purpose In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly
associated with an adverse outcome and resistance to chemotherapy-based treatment. In …
associated with an adverse outcome and resistance to chemotherapy-based treatment. In …
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
D Oscier, C Dearden, E Erem… - British journal of …, 2012 - search.ebscohost.com
The article provides information on diagnosis and management of chronic lymphocytic
leukemia (CLL). It informs about diagnosis of the CLL which includes lymphocyte …
leukemia (CLL). It informs about diagnosis of the CLL which includes lymphocyte …
Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial
A Skowronska, A Parker, G Ahmed… - Journal of Clinical …, 2012 - ascopubs.org
Purpose The prognostic significance of ATM mutations in chronic lymphocytic leukemia
(CLL) is unclear. We assessed their impact in the context of a prospective randomized trial …
(CLL) is unclear. We assessed their impact in the context of a prospective randomized trial …
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
J Hoellenriegel, GP Coffey, U Sinha, A Pandey… - Leukemia, 2012 - nature.com
Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with
downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is …
downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is …